Royalty Report: Drugs, Diagnostic, Disease – Collection: 204342

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Diagnostic
  • Disease
  • Therapeutic
  • Antibody
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 204340

License Grant
The parties desire to identify inhibitors and/or antagonists of High Mobility Group 1 Protein (HMG-1) and related proteins, including antibodies and fragments thereof, inhibitors and antagonists thereof.

Licensor grants a sole and exclusive license in the Territory, with the right to sublicense, to make, have made, use, offer for sale, sell and/or import Product(s) under Sponsored Technology.

Licensor additionally grants a first and sole option to acquire one or more licenses to Other Technology of Licensors.

License Property
Product(s) shall mean any product or service in the Field: covered by a Licensor Valid Patent Claim; made by a process covered by a Licensor Valid Patent Claim; or the manufacture, use, practice or sale of which involves the use of Sponsored Technology.

High-mobility group box 1 protein (HMGB1), a chromatin associated nuclear protein and extracellular damage associated molecular pattern molecule (DAMP), is an evolutionarily ancient and critical regulator of cell death and survival.

High mobility group box 1 protein, also known as high-mobility group protein 1 (HMG-1) and amphoterin, is a protein that in humans is encoded by the HMGB1 gene.

Field of Use
The Field shall mean the therapeutic, prophylactic and/or diagnostic use of inhibitors and/or antagonists of HMG-1 and related proteins (that is, proteins that contain the HMG boxes), including, but not limited to, antibodies and fragments thereof, inhibitors and antagonists thereof.

Licensee believe that high mobility group protein B1, or HMGB1, could be a more important therapeutic target than other cytokines in the treatment of inflammatory diseases because of the timing and the duration of HMGB1’s expression.

IPSCIO Record ID: 204339

License Grant
Licensor grants a sole and exclusive license in the Territory, with the right to sublicense, to make, have made, use, offer for sale, sell and/or import Product(s) under Licensor HMG-1 Technology and HMG-1 Patent Rights.
License Property
Licensor owns or controls certain patent rights and technology relating to inhibitors and antagonists of High Mobility Group 1 Protein (HMG-1) and is willing to license Licensee under its patent rights and technology.

High-mobility group box 1 protein (HMGB1), a chromatin associated nuclear protein and extracellular damage associated molecular pattern molecule (DAMP), is an evolutionarily ancient and critical regulator of cell death and survival.

HMGB1 is directed towards a newly-discovered pro-inflammatory cytokine.

Product(s) shall mean any product or service in the Field: covered by a Valid Patent Claim; made by a process covered by a Valid Patent Claim; or the manufacture, use, practice or sale of which includes the use of Licensor HMG-1 Technology.

Field of Use
The Field shall mean the therapeutic, prophylactic and/or diagnostic use of inhibitors and/or antagonists of HMG-1 and related proteins (that is, proteins that contain the HMG boxes), including, but not limited to, antibodies and fragments thereof, inhibitors and antagonists thereof.

IPSCIO Record ID: 204342

License Grant
Licensor grants to Licensee an exclusive license under Licensor Patent Rights and Know-How to make, have made, use, offer to sell, sell and import Product(s) in the Territory for use in the Field.
License Property
The Lead Product shall mean a Product for only one Major Indication that is the first Product for the first Major Indication as to which a Phase III Clinical Trial is initiated.  The patents and know how relate to  Antagonists of HMG-1 for Treating Inflammatory Conditions.

High-mobility group box 1 protein (HMGB1), a chromatin associated nuclear protein and extracellular damage associated molecular pattern molecule (DAMP), is an evolutionarily ancient and critical regulator of cell death and survival.

Field of Use
The Field shall mean the Development and Commercialization of Products for the treatment or prevention or amelioration of a disease, disorder or medical condition in humans or non-human animals. For purposes of clarity, Field shall not include the Development or Commercialization of products for the diagnosis of any disease, disorder or medical condition in humans or non-human animals.

IPSCIO Record ID: 203285

License Grant
Licensor grants an exclusive, worldwide, non-transferable, license, with the right to sublicense, under the Licensor Patent Rights and Know-How to make, use, including in activities directed at the research and Development of Licensed Compounds, have made, sell, have sold, offer to sell, export, import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

Licensor grants a non-transferable, non-exclusive license, with the right to sublicense, under the Licensor Other Patent Rights solely to the extent reasonably necessary to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

License Property
MS564929 Toxicology Studies means the two (2) toxicology reports due n the IND covering the BMS compound designated BMS564929, specifically the 6 onth oral toxicology studies in rats and dogs.

6,670,386 – Bicyclic modulators of androgen receptor function

The licensed compounds and patents relate to controlling various diseases and cancers.

Field of Use
The Field means the diagnosis, prevention, treatment or control of any human or animal disease, disorder or condition, excluding the prevention, treatment or control of any human or animal hyperproliferative disease, disorder or condition. For purposes of clarity, hyperproliferative diseases, disorders and conditions are those diseases, disorders or conditions which are characterized by an abnormal increase in the proliferation or accumulation of cells and include conditions such as cancers and benign hyperplasia, but not diseases, disorders or conditions incident to an abnormal increase in the proliferation or accumulation of cells.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.